GCTK - glucotrack.com Debt to Book Capitalization Ratio

Corporate company logo of GlucoTrack, Inc. (GCTK)

GlucoTrack, Inc. (GCTK) price action is under pressure from industry leaders and a lack of research funding. The ratio of debt obligations to balance sheet equity demonstrates current leverage, where the value of 0.00 captures this metric. The brand's success relies on FDA approval and the accuracy of its needle-free sensors. High growth potential is driven by the sale of software and consumables, which create a stable cash cow.

GlucoTrack - GCTK Debts to Book Capitalization (period 04/28/2023 - 10/27/2026)
Flagship merchandise of GlucoTrack Inc.

This indicator measures the proportion of borrowed funds relative to equity, allowing for an assessment of financial stability without market distortions. The metric reveals the company's dependence on creditors amid the high cost of developing non-invasive systems. By analyzing the debt-to-equity coverage ratio, an investor can see the impact of regulatory delays on the liability structure. An increase in the coefficient signals a critical level of debt load, while declining values confirm the fundamental viability of the GlucoTrack, Inc. (GCTK) business.

Competitors of GlucoTrack, Inc.

DXCM: Debts to Book Capitalization|penumbrainc.com - Debts to Book Value|Debt to Book Capitalization Ratio Novanta (NOVT)|HAE - Debt to Net Assets Ratio|INSP: Debts to Book Capitalization|PRCT (Procept) - Debts to Book Capitalization|Debt to Book Capitalization Ratio CONMED Corporation CNMD|Debts to Book Capitalization Ratio pulsebiosciences.com|InMode - Debts to Book Capitalization|Debts to Book Value Picard Medical Corp PMI|Debt to Book Value SRDX (Surmodics Corp)|SENS - Debts to Book Capitalization|Debt to Book Value NeuroPace, Inc. NPCE|TCMD - Debt to Book Capital|SANUWAVE - Debts to Book Capitalization|Outset Medical Inc (OM) - Debts to Net Assets|Debts to Book Capitalization ELMD|Debt to Book Value LENSAR Inc (LNSR)|AVITA Medical, Inc. (RCEL) - Debt to Book Value|Debt to Net Assets Ratio PROF (profoundmedical.com)|Baird Medical - Debt to Book Capitalization Ratio|Debt to Book Value EDAP TMS SA EDAP|APYX (Bovie Medical) - Debts to Book Capitalization|ICCM - Debts to Book Value|Debts to Book Capitalization pulmonx.com|TELA Bio (TELA) - Debt to Book Value Ratio|CTSO: Debts to Book Capitalization|Debts to Net Assets Sensus Healthcare Inc|Debts to Book Capitalization ZYXI (Zynex Inc)|Debt to Book Value electrocore.com (ECOR)|Debts to Book Capitalization RBOT (Vicarious Surgical)|Inspira Technologies Oxy B.H.N. Ltd. - Debts to Book Capitalization|ICU - Debt to Book Capitalization Ratio|IRIDEX Corporation (IRIX) - Debt to Book Capitalization Ratio|Debt to Book Value ibs.inc INBS|Beyond Air (XAIR) - Debt to Net Assets Ratio|Debts to Book Capitalization PFSA (Profusa Inc)|Debts to Book Value SSKN|NAOV: Debt to Book Capitalization Ratio|Debt to Net Assets Venus Concept Inc VERO|Debt to Book Value NUWE (CHF Solutions)|Debts to Book Capitalization Aethlon Medical Corp AEMD|Debts to Book Capitalization ASXC (TransEnterix)|AVGR: Debts to Net Assets|Debt to Book Capitalization Ratio Biosig Technologies (BSGM)|CUTR (Cutera Inc.) - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio KNW|Debt to Book Value Inari Medical Corp|Nevro Corp. - Debts to Book Capitalization|Debts to Book Value RSLS (reshapelifesciences.com)|SILK - Debt to Book Capitalization Ratio